<DOC>
	<DOCNO>NCT01624337</DOCNO>
	<brief_summary>Trial monthly DHA-piperaquine malaria prevention health volunteer .</brief_summary>
	<brief_title>Malaria Prevention Cambodia</brief_title>
	<detailed_description>This two arm , randomize , double-blind , placebo control cohort study determine protective efficacy monthly 2 day treatment course Dihydroartemisinin-Piperaquine ( DP ) adult volunteer malaria endemic area Cambodia .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>1 . Volunteer 1865 year age 2 . Able give inform consent 3 . Likely reside malaria endemic area duration study 4 . Available followup anticipate study duration , agree participate duration study 5 . Agrees seek outside medical care febrile illness , except emergency situation , unless refer study team 6 . Authorized local commander participate study active duty 1 . Known allergy contraindication DHA , piperaquine treatment , and/or primaquine treatment 2 . Significant acute comorbidity require urgent medical intervention 3 . Positive malaria blood smear . 4 . Treatment antimalarial drug past 30 day . 5 . Pregnant lactate female female childbearing age agree use highly effective method birth control study 6 . Significantly abnormal EKG include QTcF interval great 450ms baseline ( 470ms female ) use Fridericia 's correction 7 . Regular current use know QTc prolong medication 8 . History sudden cardiac death immediate family member , personal history know symptomatic coronary artery disease arrhythmias 9 . Judged investigator otherwise unsuitable study participation noncompliant study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>Plasmodium vivax</keyword>
</DOC>